Empowering health
About Sulfateq B.V.
Sulfateq BV is an innovative privately-held biotechnology company that is developing breakthrough compounds for the treatment of a wide range of therapeutic indications related to mitochondrial dysfunction. Our compound library emerged from research on natures natural mechanisms to cope with mitochondrial stress, including hibernation. SUL compounds have an unique mechanism-of-action and the potential to revolutionize the standard-of-care of diseases associated with a declined mitochondrial function.
We strongly believe in the potential of our science to deliver new treatments and improve quality of life for patients with non-communicable diseases involving mitochondrial dysfunction.
We are always open for new innovative partnerships. Please contact us to discuss the opportunities.
GEN Announces First Patient Dosed in Phase II Clinical Trial of SUL-238 in Parkinson’s Disease
Proof-of-concept SHEPHERD study will assess SUL-238’s effects on mitochondrial function in patients with Parkinson’s disease Ankara, Türkiye, June 08, 2026 – GEN Pharmaceuticals (GENIL.IS), Türkiye’s leading specialty pharmaceutical company, announced today that the...
Sulfateq B.V.
+31 503137464
info@sulfateqbv.com
Admiraal de Ruyterlaan 5, 9726 GN, Groningen
